94 related articles for article (PubMed ID: 25964544)
1. Class III Beta-tubulin Expression in Non-small Cell Lung Cancer: A Predictive Factor for Paclitaxel Response.
Ohashi T; Yoshimasu T; Oura S; Kokawa Y; Kawago M; Hirai Y; Miyasaka M; Aoishi Y; Kiyoi M; Nishiguchi H; Honda M; Okamura Y
Anticancer Res; 2015 May; 35(5):2669-74. PubMed ID: 25964544
[TBL] [Abstract][Full Text] [Related]
2. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
4. Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis.
Zhang HL; Ruan L; Zheng LM; Whyte D; Tzeng CM; Zhou XW
Lung Cancer; 2012 Jul; 77(1):9-15. PubMed ID: 22306125
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of stathmin is resistant to paclitaxel treatment in patients with non-small cell lung cancer.
Sun R; Liu Z; Wang L; Lv W; Liu J; Ding C; Yuan Y; Lei G; Xu C
Tumour Biol; 2015 Sep; 36(9):7195-204. PubMed ID: 25894372
[TBL] [Abstract][Full Text] [Related]
6. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
[TBL] [Abstract][Full Text] [Related]
7. Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial.
Vilmar AC; Santoni-Rugiu E; Sørensen JB
Clin Cancer Res; 2011 Aug; 17(15):5205-14. PubMed ID: 21690572
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status.
Edelman MJ; Schneider CP; Tsai CM; Kim HT; Quoix E; Luft AV; Kaleta R; Mukhopadhyay P; Trifan OC; Whitaker L; Reck M
J Clin Oncol; 2013 Jun; 31(16):1990-6. PubMed ID: 23589560
[TBL] [Abstract][Full Text] [Related]
9. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
Leskelä S; Leandro-García LJ; Mendiola M; Barriuso J; Inglada-Pérez L; Muñoz I; Martínez-Delgado B; Redondo A; de Santiago J; Robledo M; Hardisson D; Rodríguez-Antona C
Endocr Relat Cancer; 2011 Feb; 18(1):85-95. PubMed ID: 21051560
[TBL] [Abstract][Full Text] [Related]
10. The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy.
Kaira K; Takahashi T; Murakami H; Shukuya T; Kenmotsu H; Ono A; Naito T; Tsuya A; Nakamura Y; Endo M; Kondo H; Nakajima T; Yamamoto N
Int J Clin Oncol; 2013 Jun; 18(3):371-9. PubMed ID: 22358390
[TBL] [Abstract][Full Text] [Related]
11. Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer.
Ikeda S; Takabe K; Suzuki K
Pathol Int; 2009 Dec; 59(12):863-7. PubMed ID: 20021611
[TBL] [Abstract][Full Text] [Related]
12. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
Azuma K; Sasada T; Kawahara A; Hattori S; Kinoshita T; Takamori S; Ichiki M; Imamura Y; Ikeda J; Kage M; Kuwano M; Aizawa H
Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
[TBL] [Abstract][Full Text] [Related]
13. Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.
Miyata Y; Matsuo T; Nakamura Y; Yasuda T; Ohba K; Takehara K; Sakai H
Anticancer Res; 2018 Mar; 38(3):1629-1635. PubMed ID: 29491095
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
Toffart AC; Timsit JF; Couraud S; Merle P; Moro-Sibilot D; Perol M; Mastroianni B; Souquet PJ; Girard N; Jeannin G; Romand P; Chatellain P; Vesin A; Brambilla C; Brambilla E
Lung Cancer; 2014 Feb; 83(2):182-8. PubMed ID: 24388706
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients.
Jakobsen JN; Santoni-Rugiu E; Sørensen JB
Cancer Chemother Pharmacol; 2014 Jan; 73(1):43-51. PubMed ID: 24220933
[TBL] [Abstract][Full Text] [Related]
16. [Prediction of a non-small cell lung cancer sensitivity to cisplatin and paclitaxel based on the marker genes expression].
Boiarskikh UA; Kondrakhin IuV; Evshin IS; Sharipov RN; Komel'kov AV; Musatkina EA; Chevkina EM; Sukoian MA; Kolpakov FA; Kashkin KN; Filipenko ML
Mol Biol (Mosk); 2011; 45(4):652-61. PubMed ID: 21954597
[TBL] [Abstract][Full Text] [Related]
17. Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy.
Wang TB; Zhang NL; Wang SH; Li HY; Chen SW; Zheng YG
Genet Mol Res; 2014 May; 13(2):3704-10. PubMed ID: 24854656
[TBL] [Abstract][Full Text] [Related]
18. Is class III beta-tubulin a true predictive marker of sensitivity to vinorelbine in non-small cell lung cancer? Chemosensitivity data evidence.
Hirai Y; Yoshimasu T; Oura S; Ota F; Naito K; Nishiguchi H; Hashimoto S; Okamura Y
Anticancer Res; 2011 Mar; 31(3):999-1005. PubMed ID: 21498728
[TBL] [Abstract][Full Text] [Related]
19. Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype.
Tseden-Ish M; Choi YD; Cho HJ; Ban HJ; Oh IJ; Kim KS; Song SY; Na KJ; Ahn SJ; Choi S; Kim YC
Respirology; 2012 Jan; 17(1):127-33. PubMed ID: 21899657
[TBL] [Abstract][Full Text] [Related]
20. Combination of microtubule associated protein-tau and β-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer.
Yu J; Gao J; Lu Z; Gong J; Li Y; Dong B; Li Z; Zhang X; Shen L
Eur J Cancer; 2014 Sep; 50(13):2328-35. PubMed ID: 25016949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
